Phase 3 NEC Clinical Trials
67 recruitingPhase 3
What is a Phase 3 trial?
Phase 3 trials compare the new treatment against the current standard of care in large groups, often hundreds to thousands of participants. Successful Phase 3 results are typically required for regulatory approval.
Showing 1–20 of 67 trials
Recruiting
Phase 3
Testing the Addition of an Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery to the Usual Surgery Alone for Treating Advanced Skin Cancer
Stage III Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8Eyelid Squamous Cell Carcinoma+17 more
National Cancer Institute (NCI)420 enrolled206 locationsNCT06568172
Recruiting
Phase 3
Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
Metastatic Head and Neck Squamous Cell CarcinomaStage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8Recurrent Head and Neck Squamous Cell Carcinoma+18 more
National Cancer Institute (NCI)158 enrolled176 locationsNCT06589804
Recruiting
Phase 3
Intra-arterial Tenecteplase for Acute Medium Vessel Occlusion Stroke
Ischemic StrokeMedium Vessel OcclusionEndovascular Treatment+1 more
Beijing Tiantan Hospital488 enrolled1 locationNCT07357987
Recruiting
Phase 3
Lymphocyte-Sparing And Radio-Immunotherapy in Head and Neck Carcinoma
Oropharynx CancerLarynx CancerHypopharynx Cancer+1 more
Centre Leon Berard460 enrolled8 locationsNCT06706401
Recruiting
Phase 3
A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)
Head and Neck Squamous Cell Carcinoma
Merus B.V.700 enrolled197 locationsNCT06525220
Recruiting
Phase 3
Palbociclib and Cetuximab Versus Cetuximab Monotherapy for Patients With CDKN2A-altered, HPV-unrelated Head and Neck Squamous Cell Carcinoma Who Experienced Disease Progression on a PD-1/L1 Inhibitor
HPV-unrelated Head and Neck Squamous Cell Carcinoma
Washington University School of Medicine81 enrolled5 locationsNCT04966481
Recruiting
Phase 2Phase 3
A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1
Unresectable Head and Neck Squamous Cell CarcinomaMetastatic Head and Neck CancerRecurrent Head and Neck Cancer
BioNTech SE350 enrolled193 locationsNCT04534205
Recruiting
Phase 3
Postoperative Radiotherapy Combined With Nimotuzumab Followed by Benmelstobart in High-Risk Patients With Head and Neck Squamous Cell Carcinoma
Head & Neck CancerPostoperative Adjuvant TreatmentHead & Neck Squamous Cell Carcinoma
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University370 enrolled1 locationNCT07445048
Recruiting
Phase 3
Palliative Steroeotactic Body Radiotherapy vs Palliative Standard Radiotherapy in Patients With Advanced Head and Neck Cancer
Advanced Head and Neck Cancer
Canadian Cancer Trials Group196 enrolled6 locationsNCT06641791
Recruiting
Phase 2Phase 3
A Trial Evaluating Omission of Radiotherapy to Regional Lymphatic's
Head and Neck Cancer
All India Institute of Medical Sciences396 enrolled1 locationNCT07528495
Recruiting
Phase 3
A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
Squamous Cell Carcinoma of Head and Neck
Janssen Research & Development, LLC500 enrolled160 locationsNCT07276399
Recruiting
Phase 3
High-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Concurrent Chemoradiation for Head and Neck Cancer
Head and Neck Squamous Cell CarcinomaStage III Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8+2 more
Alliance for Clinical Trials in Oncology228 enrolled187 locationsNCT06992427
Recruiting
Phase 3
Becotatug Vedotin (MRG003) in Combination With PD-1 Inhibitor Versus PD-1 Inhibitor for the Treatment of EGFR-positive, CPS≥1 Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma
Locally Advanced Head and Neck Squamous Cell Carcinoma
Ming-Yuan Chen430 enrolled1 locationNCT07524452
Recruiting
Phase 3
A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients
Head and Neck Squamous Cell Carcinoma
Merus B.V.500 enrolled208 locationsNCT06496178
Recruiting
Phase 3
An Imaging Agent (Pafolacianine) for Identifying Lesions in Pediatric Patients With Primary or Metastatic Solid Tumors
Malignant Abdominal NeoplasmChildhood Malignant Solid NeoplasmChildhood Malignant Thoracic Neoplasm+3 more
Mayo Clinic20 enrolled1 locationNCT06915727
Recruiting
Phase 3
Development and Application of a Nurse-Led Preemptive Symptom Management Protocol for Head and Neck Cancer Patients Undergoing Radiation Therapy
Head and Neck Cancer
West China Hospital170 enrolled1 locationNCT07467083
Recruiting
Phase 3
Comparing Postoperative Adjuvant Cisplatin Concurrent Chemoradiotherapy With Adjuvant Radiotherapy Alone for Intermediate-risk Head and Neck Squamous Cell Carcinoma
Squamous Cell Cancer of Head and Neck (SCCHN)
Sun Yat-sen University386 enrolled7 locationsNCT07125755
Recruiting
Phase 2Phase 3
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
Metastatic Head and Neck Squamous Cell CarcinomaRecurrent Head and Neck Squamous Cell Carcinoma
Bicara Therapeutics650 enrolled129 locationsNCT06788990
Recruiting
Phase 3
A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy
Locally Advanced Head and Neck Squamous Cell Carcinoma
AstraZeneca1,145 enrolled305 locationsNCT06129864
Recruiting
Phase 3
Re-Radiochemotherapy and Pembrolizumab vs. Immuno(Chemo)Therapy for Locoregionally Recurrent PD-L1 Positive (CPS≥1) HNSCC
Recurrent Head and Neck Squamous Cell Carcinoma
Universität des Saarlandes214 enrolled18 locationsNCT07026474